SCHEMBL14033441

SCHEMBL14033441

OC(c1ccccc1)c1ccc(C(F)(F)F)nc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.49
P2RX7 Q99572 8/20 0.48
ADORA2A P29274 2/20 0.48
ADORA1 P30542 1/20 0.48
TRPV4 Q9HBA0 1/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
HDAC4 P56524 1/20 0.40
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
BRD4 O60885 1/20 0.38
CYP17A1 P05093 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14033926 0.85 P2RX7 (0.44) P2RX7TRPV4BRD4
SCHEMBL14803652 0.83 SMN1; SMN2 (0.49) SMN1; SMN2P2RX7ADORA2AADORA1CA12
SCHEMBL14033326 0.79 P2RX7 (0.48) P2RX7TRPV4HDAC4ATM
SCHEMBL28009191 0.79 P2RX7 (0.45) P2RX7TRPV4HDAC4ATM
SCHEMBL16462564 0.77 P2RX7 (0.52) P2RX7TRPV4
SCHEMBL28869188 0.77 TRPV4 (0.48) P2RX7TRPV4BRD4
SCHEMBL27823408 0.77 TRPV4 (0.48) P2RX7TRPV4BRD4
SCHEMBL30003924 0.77 TRPV4 (0.48) P2RX7TRPV4BRD4
SCHEMBL485441 0.77 TRPV4 (0.48) P2RX7TRPV4BRD4
SCHEMBL16463713 0.76 ALDH1A1 (0.46) SMN1; SMN2P2RX7TRPV4ATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed